^
Association details:
| Biomarker: | TFG-ROS1 fusion |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P89.10 - Genomic Alteration Features and Targeted Therapy Opportunities of Primary Thoracic Sarcoma Patients
Published date:
01/12/2021
Excerpt:
We also observed a 61-year-old male patient benefiting from afatinib, who was diagnosed with T1N3M0 lung adenocarcinoma harboring an EGFR KDD (exon18-25dup). The patient showed partial response (PR) 1 month after afatinib treatment with a progression-free survival (PFS) of 11 months and counting.
